Bortezomib and Insulin human inhaled Inhalation
Determining the interaction of Bortezomib and Insulin human inhaled Inhalation and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Bortezomib can sometimes affect blood glucose levels. Both hyperglycemia (high blood glucose) and hypoglycemia (low blood glucose) have been reported. Your blood glucose should be closely monitored during treatment with bortezomib so that your diabetic regimen may be adjusted, if needed. Let your doctor know if you experience hyperglycemia or hypoglycemia, or if you notice a loss of blood glucose control. Symptoms of hyperglycemia may include increased thirst, increased hunger, and increased urination. Symptoms of hypoglycemia include headache, dizziness, drowsiness, nervousness, confusion, tremor, nausea, hunger, weakness, perspiration, palpitation, and rapid heartbeat. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:MONITOR: Bortezomib may interfere with the therapeutic effects of insulin and other antidiabetic agents. Both hypoglycemia and hyperglycemia have been reported in diabetic patients during clinical trials. The mechanism by which bortezomib may affect blood glucose has not been established.
MANAGEMENT: Blood glucose should be closely monitored when bortezomib is prescribed to patients receiving insulin or other antidiabetic agents. Patients should learn to recognize the symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypo- or hyperglycemia occur during bortezomib therapy, patients should initiate appropriate remedial therapy immediately and contact their physician. Dosage adjustments may be required if an interaction is suspected.
- "Product Information. Velcade (bortezomib)." Millennium Pharmaceuticals Inc, Cambridge, MA.
Generic Name: insulin inhalation, rapid acting
Brand name: Afrezza, Exubera, EXUBERA Combination Pack 12, EXUBERA Combination Pack 15, EXUBERA Kit, Afrezza 4 unit- 8 unit, Afrezza 8 unit- 12 unit, Afrezza Titration Pack, Exubera
Synonyms: Insulin (inhalation), Insulin (Oral Inhalation)
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Bortezomib-Insulin human regular Injection
- Bortezomib-Insulin inhalation
- Bortezomib-Insulin isophane
- Bortezomib-Insulin isophane and insulin regular
- Bortezomib-Insulin lispro
- Bortezomib-Insulin Lispro (U-100) Cartridges and Pens
- Insulin human inhaled Inhalation-Bortezomib Intravenous
- Insulin human inhaled Inhalation-Bosentan
- Insulin human inhaled Inhalation-Bosentan Tablets
- Insulin human inhaled Inhalation-Bosentan Tablets for Oral Suspension
- Insulin human inhaled Inhalation-Bosulif
- Insulin human inhaled Inhalation-Bosutinib